United States

People: Celgene Corp (CELG.O)

CELG.O on Nasdaq

18 Aug 2017
Change (% chg)

$0.07 (+0.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Casey, Michael 

Mr. Michael D. Casey serves as Lead Independent Director of Celgene Corp. He is Chairman of the Nominating Committee and a member of the Executive Committee since December 2006, and a member of the Management Compensation and Development Committee (referred to as the Compensation Committee) since April 2006. Mr. Casey was a member of the Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a Director of Abaxis Inc. (and a member of the Compensation Committee). Mr. Casey served as a Director of Allos Therapeutics, Inc. through January 2010, AVI BioPharma (now Sarepta Therapeutics, Inc.) through June 2010 and Durect Corporation through December 2013.Mr. Casey brings to his service as a director his significant experience and leadership as President, Chief Executive Officer and senior officer of several national pharmaceutical companies. In addition to those listed above, he has previously served as a director of several other pharmaceutical/biotech companies.

Basic Compensation

Total Annual Compensation, USD 126,250
Restricted Stock Awards, USD 112,478
Long-Term Incentive Plans, USD --
All Other, USD 337,393
Fiscal Year Total, USD 576,121

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Hugin


Scott Smith


Mark Alles


Peter Kellogg


Terrie Curran


Michael Pehl

As Of  30 Dec 2016